Contrasting Endonovo Therapeutics (OTCMKTS:ENDV) and GigCapital5 (NYSE:GIA)

Endonovo Therapeutics (OTCMKTS:ENDV) and GigCapital5 (NYSE:GIA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for Endonovo Therapeutics and GigCapital5, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	N/A
GigCapital5	0	0	0	0	N/A

Valuation & Earnings

This table compares Endonovo Therapeutics and GigCapital5″s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$140,000.00	2.83	$6.93 million	N/A	N/A
GigCapital5	N/A	N/A	-$2.77 million	N/A	N/A

Endonovo Therapeutics has higher revenue and earnings than GigCapital5.

Profitability

This table compares Endonovo Therapeutics and GigCapital5’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	4,911.97%	-29.58%	755.18%
GigCapital5	N/A	N/A	-14.85%

Risk and Volatility

Endonovo Therapeutics has a beta of -1.88, suggesting that its share price is 288% less volatile than the S&P 500. Comparatively, GigCapital5 has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.

Insider & Institutional Ownership

27.3% of GigCapital5 shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 75.4% of GigCapital5 shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About GigCapital5

GigCapital5, Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Palo Alto, California.GigCapital5, Inc operates as a subsidiary of GigAcquisitions5, LLC